Methodological quality of preclinical stroke studies is not required for publication in high-impact journals

J Cereb Blood Flow Metab. 2010 Sep;30(9):1619-24. doi: 10.1038/jcbfm.2010.74. Epub 2010 Jun 2.


Omitting quality characteristics in animal stroke studies leads to an overestimation of the efficacy of candidate stroke drugs. Nevertheless, the methodological quality of preclinical stroke studies is often limited. As publishing of research results in high-impact journals is an important motivation for scientists, we analyzed whether study quality predicts high-impact publishing. Animal stroke studies of neuroprotective drugs that were recently investigated in clinical phase II/III trials were included in the analysis. Data on the study quality and other important study characteristics were extracted. Regression analyses were performed to estimate the effect of the study characteristics on the journal's impact factor. We identified 117 studies that investigated 12 different drugs. Study quality was not associated with the impact factor before (beta=-0.2, P=0.50) and after adjustment for other study characteristics (beta=-0.3, P=0.19). There was a significant association of the number of investigated mechanisms and applied techniques with the impact factor (beta=1.4, P<0.0001). Our findings show that the quality of animal experimental stroke studies is not relevant for publishing in high-impact journals. The major predictor for accepting preclinical stroke studies in high-impact journals is the complexity of the investigation into a stroke drug's mode of action.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bibliometrics*
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Data Interpretation, Statistical
  • Fibrinolytic Agents / therapeutic use
  • Neuroprotective Agents / therapeutic use
  • Periodicals as Topic / standards*
  • Publications / standards*
  • Research Design
  • Stroke / drug therapy
  • Stroke / physiopathology*
  • Thrombolytic Therapy


  • Fibrinolytic Agents
  • Neuroprotective Agents